

PHARMACY POLICY STATEMENT Kentucky Medicaid	
DRUG NAME	Orkambi (lumacaftor/ivacaftor)
BILLING CODE	Must use valid NDC code
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
COVERAGE REQUIREMENTS	Prior Authorization Required (Preferred Product) QUANTITY LIMIT – 120 tablets per 30 days
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Orkambi (lumacaftor/ivacaftor) is a **preferred** product and will only be considered for coverage under the **pharmacy** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

CYSTIC FIBROSIS

For **initial** authorization:

1. Member must be 6 years of age or older; AND
2. Medication must be prescribed by a pulmonologist or an infectious disease specialist; AND
3. Member has had genetic testing documented in chart notes with two copies (homozygous) of the F508del mutation (F508del/F508del) in their CFTR gene.
4. **Dosage allowed:** Adults and pediatric patients age 12 years and older: two tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) taken orally every 12 hours. Pediatric patients age 6 through 11 years: two tablets (each containing lumacaftor 100 mg/ivacaftor 125 mg) taken orally every 12 hours.

If member meets all the requirements listed above, the medication will be approved for 3 months.

For **reauthorization**:

1. Member must be in compliance with all other initial criteria; AND
2. Member's adherence to medication is confirmed by claims history.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

CareSource considers Orkambi (lumacaftor/ivacaftor) not medically necessary for the treatment of the diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
06/12/2017	New policy for Orkambi created. Not covered diagnosis added.

References:

1. Orkambi [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; 2016. Accessed March 6, 2017.
2. Orkambi. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: <http://www.micromedexsolutions.com>. Accessed March 6, 2017.
3. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville



(MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. Available: <https://www.guideline.gov>. Accessed March 6, 2017.

Effective date: 08/09/2017

Revised date: 06/12/2017